Zobrazeno 1 - 10
of 2 818
pro vyhledávání: ''
Publikováno v:
BMJ case reports. 14(11)
This is a case of a young woman who developed neurological and psychiatric symptoms 3 days after resection of an immature teratoma. She was diagnosed with anti-NMDA receptor encephalitis via positive serum antibody titres, which was later confirmed w
Autor:
Karen Cadoo, Steven C. Plaxe, Janiel M. Cragun, Esteban Rodrigo Imedio, Setsuko K. Chambers, Ganesh Mugundu, Jill J.J. Geenen, Gottfried E. Konecny, Suzanne F. Jones, Lee-may Chen, Tiffany A. Troso-Sandoval, Erika Hamilton, Zhongwu Lai, David R. Spigel, Kathleen N. Moore, Amit M. Oza, Sharad A. Ghamande, Daniel Lewis Spitz, Sanjeev Kumar, Juliann Chmielecki
Publikováno v:
Clinical Cancer Research. 28:36-44
Purpose: This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer. Patients and Methods: Women with histologica
Publikováno v:
Internal Medicine. 61:87-90
A 56-year-old woman with rheumatoid arthritis who had been taking methotrexate (MTX) for six years visited our hospital with dyspnea and dizziness. Abdominal ultrasonography revealed mild splenomegaly. Laboratory examinations showed a marked elevatio
Autor:
Ainsley Barry, Tina Mills-Baldock, Sam Khan, Timothy Iveson, Athanasios Pouptsis, Chloe Holden, Anne Thomas, Bryony Eccles, Liyana Satterthwaite, Vasileios Angelis, Christina Karampera, Paul Ross, Sherif Abdel-Raouf, Alicja Synowiec, Kai-Keen Shiu, Maria Martinou, M Hill, Meera Chauhan, Mark Baxter, Chara Stavraka, Janet Graham, Sally Young
Publikováno v:
Clinical Colorectal Cancer. 20:342-349
BACKGROUND The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study. PATIENT AND METHODS We performed
Autor:
Shogo Teraoka, Atsushi Takenaka, Katsuya Hikita, Masashi Honda, Hideto Iwamoto, Shuichi Morizane, Bunya Kawamoto, Noriya Yamaguchi, Tetsuya Yumioka, Ryutaro Shimizu
Publikováno v:
Anticancer Research. 41:5767-5773
BACKGROUND This study aimed to investigate the response to platinum-based chemotherapy rechallenge in patients with pembrolizumab-refractory urothelial carcinoma. PATIENTS AND METHODS We retrospectively reviewed 14 patients with pembrolizumab-refract
Autor:
Timothy F. Burns, Patrick J. Ward, D. Ross Camidge, Martina M. Koch, Carrianne Ludwig, Christine L. Hann, Maulik Patel, Afshin Dowlati, Daniel Morgensztern, Chris Chen, Halla Nimeiri, Philip Komarnitsky
Publikováno v:
Journal of Thoracic Oncology. 16:1582-1588
Introduction Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting DLL3, a Notch pathway ligand highly expressed on SCLC cells. Rova-T was evaluated alone or in combination with platinum-based chemotherapy (cisplatin or carboplatin
Autor:
Yukinori Kurokawa, Junya Fujita, Tomono Kawase, Yutaka Kimura, Hiroshi Imamura, Hisato Kawakami, Masahiro Goto, Kazuhiro Nishikawa, Norimasa Fukushima, Shugo Ueda, Naotoshi Sugimoto, Jin Matsuyama, Taroh Satoh, Daisuke Sakai, Takao Tamura, Toshio Shimokawa
Publikováno v:
International Journal of Clinical Oncology. 26:1871-1880
To compare irinotecan-alone, paclitaxel-alone, and each combination chemotherapy with S-1 in patients with advanced gastric cancer (AGC) that is refractory to S-1 or S-1 plus cisplatin (SP). Patients with AGC after first-line chemotherapy with S-1 or
Autor:
Hilary Coye, Mazyar Shadman, Karolyn Morris, Christen N. Martino, Andrei R. Shustov, Edus H. Warren, Brian G. Till, Heather Rasmussen, Jenna M. Voutsinas, Sandra L Bhark, Jonathan R. Fromm, Chaitra S. Ujjani, Ryan D. Cassaday, Edward N. Libby, Mary Philip, Andrew J. Cowan, Stephen D. Smith, Sanaz Behnia, Ryan C. Lynch, Ajay K. Gopal
Publikováno v:
The Lancet Haematology. 8:e562-e571
Summary Background Relapsed or refractory classical Hodgkin lymphoma could be treated with multiagent salvage chemotherapy followed by autologous haematopoietic stem-cell transplantation. The aim of this study is to establish the safety and activity
Autor:
Adity Chakraborty, Shibashis Deb, Amlan Jyoti Nath, Abhinandan Bhattacharjee, Aakanksha Rathor
Publikováno v:
The Egyptian Journal of Otolaryngology, Vol 37, Iss 1, Pp 1-9 (2021)
BackgroundCisplatin is a frontline anticancer drug routinely used as part of concurrent chemoradiation administered at 3-weekly (100 mg/m2) dose. However, its role as fractionated weekly dose has achieved favorable outcome in patients with locally ad
Publikováno v:
Journal of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine, Vol 35, Iss 4, Pp 1929-1934 (2021)
Journal of Veterinary Internal Medicine, Vol 35, Iss 4, Pp 1929-1934 (2021)
Background Doxorubicin-based chemotherapy after splenectomy remains the standard of care for hemangiosarcoma in dogs, but prognosis is generally poor. Hypothesis/objectives To determine clinical outcome with carboplatin chemotherapy after splenectomy